Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. - Vilsbøll,T.; Zdravkovic,M.; Le-Thi,T. (Diabetes Care, 2007)